ESC Premium Access

Characterization of residual lipid-rich plaques despite achieving LDL-C <1.8mmol/l with a statin in patients with coronary artery disease: insights from the REASSURE-NIRS registry

Congress Session

About the speaker

Doctor Satoshi Kitahara

National Cerebral & Cardiovascular Center, Suita (Japan)
0 follower

178 more presentations in this session

The quest for GRACE 3.0: improving our beloved risk score with machine learning

Speaker: Doctor J. Sousa (Coimbra, PT)

Thumbnail

Percutaneous coronary interventions in patients with left main coronary artery pseudobifurcation lesions: 5-years follow-up

Speaker: Associate Professor D. Maximkin (Moscow, RU)

Thumbnail

Use of intima media thickness in the assessment of the development of preclinical atherosclerosis

Speaker: Associate Professor R. Najafov (Baku, AZ)

Thumbnail

Long term outcomes of patients with chronic inflammatory diseases after percutaneous coronary intervention

Speaker: Doctor O. Kobo (Hadera, IL)

Thumbnail

Feasibility, safety and long term outcomes of complex left main bifurcation treatment using the nano inverted t stenting: a multicentre registry

Speaker: Associate Professor G. Rigatelli (Rovigo, IT)

Thumbnail

Access the full session

Coronary Artery Disease (Chronic)/Chronic Coronary Syndromes ePosters

Speakers: Doctor S. Kitahara, Doctor J. Sousa, Associate Professor D. Maximkin, Associate Professor R. Najafov, Doctor O. Kobo...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

27 August 2021

ESC Premium Access

Treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe: baseline demographics from the multinational observational SANTORINI study

27 August 2021

ESC Premium Access

Hospitalized patients with hypertension and moderate COVID-19 benefit from continuing ACEIs and ARBs: Insights from the BRACE CORONA trial

27 August 2021

This platform is supported by

logo Novo Nordisk